港股異動 | 康哲藥業(0867.HK)續漲7% 股價再創新高
格隆匯6月10日丨康哲藥業(0867.HK)股價延續近期強勢,盤中最高見22.75港元續創新高,現報22.55港元,漲幅7.38%,最新總市值557.16億港元,年內累計漲超160%。6月9日,康哲藥業創新藥甲氨蝶呤注射液(預充式)中國IND申請獲得國家藥品監督管理局藥品審評中心受理。甲氨蝶呤注射液(預充式)採用皮下給藥,擁有更低的副作用(尤其胃腸道不良反應少)、更好的生物利用度、更佳的臨牀應答、以及更方便的劑量管理,在療效、安全耐受性和依從性之間取得了良好的平衡。該產品已在歐洲獲批上市。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.